Abstract
Plasmodium vivax malaria is one of the most common vector-borne parasitic infections worldwide. P. vivax clinical manifestations include lung injury, renal dysfunction, hepatic dysfunction and extreme thrombocytopenia etc. P. vivax contributes around 70% of malaria cases in Pakistan with variable severity, but 47% of total severe vivax malaria cases have been reported in India. Elimination of P. vivax is very difficult because of its ability to form dormant stages of the liver. Insecticidetreated nets and insecticides are used to control malaria in malaria-endemic regions. Chloroquine is used as the first line of the agent in P. vivax malaria treatment. ACTs are also very effective because of their fast medical and parasitological response than that of chloroquine. Due to increasing drug resistance among P. vivax, scientists have tested with mass drug administration to eradicate malaria. In spite of all this, the P. vivax vaccine would be the last resort in the eradication of P. vivax malaria.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Global Immunological & Infectious Diseases Review
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
